HOLISTA COLLTECH LIMITED — AGM Information 2021

Jul 29, 2021

AGM Presentation July 2021

==> picture [167 x 156] intentionally omitted <==

Company Overview (ASX: HCT) World-leading technologies & global reach

Holista Colltech is an emerging Australian developer of unique health and wellness products in the US$4.5 trillion Global Health and Wellness Industry*

https://globalwellnessinstitute.org/press-room/statistics-and-facts/

Key Market Stats (as of 29 July 2021)
Market Cap	$16.4m
Cash Balance	$2.1m
52-week Trading Range	4.8¢ - 20.0¢
Average Daily Vol.	396,522
No. of Shares on Issue	275.4m
Top 20 Shareholders	65%

✓Global reach with customers in Asia, US and Australia

✓Successfully commercialised portfolio of patentprotected/proprietary technologies

✓Established track record with ~$7m in FY20 sales

✓Key products include low-GI food ingredients used by leading food manufacturers, all-natural sanitisers for consumer and industrial applications, market leading dietary supplements and globally unique ovine collagen.

==> picture [251 x 97] intentionally omitted <==

2 AGM Presentation July 2021

Resilient 2020 Revenue Improved outlook

==> picture [35 x 41] intentionally omitted <==

2020 full-year revenue steady at $7.1m despite COVID-19 global crisis.

==> picture [36 x 35] intentionally omitted <==

Healthy Food Ingredients sales continues to grow strongly on the back of orders from Costanzo’s

==> picture [34 x 147] intentionally omitted <==

Infection Control Solutions delivered maiden contribution to Group results

Collagen and Dietary Supplement businesses rebounding steadily in 1H2021 after COVID impact

Positive 2021 outlook with improved results expected

==> picture [43 x 44] intentionally omitted <==

Improved profitability from cost efficiency program (targeting $0.5m in savings)

3 AGM Presentation July 2021

Global Revenue FY2020 Diversifying the income base

==> picture [536 x 7] intentionally omitted <==

==> picture [332 x 344] intentionally omitted <==

----- Start of picture text -----

Infection
Control Food
Ovine $0.67m Ingredients
$1.03m
Collagen
$0.17m
Dietary
Supplements
$5.23m
----- End of picture text -----

Growth potential in Ovine Collagen, Infection Control and Food Ingredients

Infection Control is newest division and its first year contribution (FY20) accounted for ~10% of Group revenue

Holista’s sales network across the United spans States, Australia and Malaysia

Strong diversification of income streams is key to building a defensive earnings profile for the Group

4 AGM Presentation July 2021

Sales Growth Across All Divisions Continuing growth momentum

Divisional Sales Revenue* ($K)

0 500 1000 1500 2000 2500 3000 3500 4000
		1H2020 1H2021

Total 1H21 Group Sales increased by 29.2% to $3.6 million * compared to 1H20 with all divisions contributing to the improved results Division PCP Change Food Ingredients 158.9% Supplements 9.3% Infection Control 7.2% Ovine Collagen 611.1%

*Final 1H2021 figures are subject to audit

Food Ingredients Supplements Infection Control Ovine Collagen

5 AGM Presentation July 2021

Year of Achievements Foundations for a stronger FY21

1[st] order Exclusive received Launch “List distribution for SARSN” HVAC agreement CoV-2 test 1[st] order for solution to for ovine kits GI-Lite[TM] control collagen Pathfrom airborne into China Away® Costanzo’s COVID Signs deal successfully for US with tested launch Costanzo’s against Maiden to launch SARS-CoV-2 sales of world’s 80Less sugar lowest GI substitute clean label white bread in US

==> picture [896 x 54] intentionally omitted <==

----- Start of picture text -----

FY2020 - FY2021
----- End of picture text -----

AGM Presentation July 2021

6

Business Divisions Growth engines

==> picture [64 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

• Fastest growing •Newest business division in FY21 (FY20 1[st] year • Momentum contribution) expected to •Strong multi-year continue growth potential • GI Lite[TM] for •Patented allhealthier breads, natural sanitisers tortilla, etc •Unique delivery • 80Less[TM] sugar via HVAC substitute, systems via tapping on patented M3® increasing technology awareness of the •Patented nasal dangers of sugar balm formulation

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

•Largest sales/profit contributor •Recovering steadily from COVID-19 impact •Market leading vitamin brand in Malaysia

•1[st] to produce ovine collagen from Australian Sheep •Patented processes •Australian collagen highly prized due to disease-free status •Product currently sold to cosmetics manufacturers

7 AGM Presentation July 2021

Healthy Food Ingredients Developments & update

==> picture [756 x 7] intentionally omitted <==

Holista has a full range of low GI foods, tested and validated by the University of Sydney*

==> picture [147 x 117] intentionally omitted <==

==> picture [147 x 119] intentionally omitted <==

==> picture [147 x 113] intentionally omitted <==

==> picture [147 x 111] intentionally omitted <==

Low GI White Bread advertisement, St Louis trade show participation, display at Wegman Store shelfs in the US --pictures courtesy of Costanzo’s.

Costanzo’s launched world’s lowest GI clean-label white bread in the US using Holista’s GI Lite[TM] in April 2021

Costanzo’s Low GI White Bread sold in US in supermarket chains like Wegmans, Tops, Price Right, etc

Costanzo’s on track on the agreement for GI Lite[TM]

F&B manufacturer Rex Industry using Holista’s 80Less[TM] sugar substitute in ~8 beverage products

Holista is developing 2 new health products for Rex (cocoa milk powder and Ready To Drink cocoa formulation)

Relaunched Holista Foods Inc Website

https://holistafoods.com/ to better capitalise on US opportunities

==> picture [110 x 99] intentionally omitted <==

*Independent testing by University of Sydney showed GI Lite[TM] lowered the GI in food by 30% to 40% and has a score of 46 in white bread.

8 AGM Presentation July 2021

Infection Control Developments & update

NatShield[TM] & Path-Away®

• ✓ Secured distribution rights for Path-Away (active ingredient in NatShield) and acquired Protectene® from GICC

• ✓ Microbac tests shows Path-Away kills 99.9% of COVID-19 virus (SARS-CoV-2) within 2 minutes

• ✓ Undertaking studies to show Path-Away remains effective on hard surface and skin for 8-12 hours

• ✓ Nasal balm (using Protectene as active ingredient) to launch in US, Singapore & Malaysia by Q4 2021* ✓ TGA approved Natshield™as cosmetic allowing claims of killing 99.99% of germs (sanitisers & wipes)

• ✓ Wipes developed by Cool Hands in Netherlands in collaboration with GICC to be launched in Malaysia by Q4 2021

*Subject to regulatory approval

==> picture [123 x 35] intentionally omitted <==

==> picture [130 x 18] intentionally omitted <==

==> picture [98 x 29] intentionally omitted <==

==> picture [215 x 178] intentionally omitted <==

==> picture [79 x 183] intentionally omitted <==

==> picture [112 x 29] intentionally omitted <==

==> picture [79 x 158] intentionally omitted <==

9 AGM Presentation July 2021

Infection Control Developments & update

M3® HVAC Solution

• ✓ Signed term sheet to form JV with GICC to pursue opportunities outside of North America

• ✓ M3 exempted in Australia for heating, ventilation and air-conditioning (HVAC) application

• ✓ Submitted TGA application for “List N” Bioesque formulated with Thymox* for fogging and hard surface disinfection

• ✓ Bioesque formulated with Thymox* to be offered in place of Natshield™for use with M3[+]

==> picture [235 x 163] intentionally omitted <==

==> picture [113 x 98] intentionally omitted <==

==> picture [127 x 104] intentionally omitted <==

==> picture [111 x 89] intentionally omitted <==

==> picture [121 x 95] intentionally omitted <==

• Bioesque formulated with Thymox is on the US EPA List N and made by Laboratoire M2, which signed a supply agreement with GICC

• + Bioesque formulated with Thymox to replace Natshield as Natshield is not N-Listed

AGM Presentation July 2021

10

Infection Control Latest Revenue Stream

COVID-19 Test Kits

• ✓ Secured exclusive distribution rights to 15min rapid test kits made by Guangdong Hecin Scientific Inc ✓ Approved in Malaysia (Emergency Use Authorisation)

• ✓ Won first order in Malaysia last month to supply 15,000 test kits with ongoing follow-up orders expected

• ✓ In the process of securing next order of 30,000 kits for the Malaysian market

• ✓ Distribution rights for UK, Malaysia and 10 other Asian countries

• ✓ Registration initiated in Singapore, Canada, UK and ongoing discussion with other countries

• ✓ Secured exclusive distribution rights for GeneSign Biotech Co Ltd

• ✓ Also acquired Antigen Rapid test kits (saliva, blood and breath) and Antibody Rapid Test kit

✓ Completed co-development of Track and Test App link to mobile application.

==> picture [208 x 74] intentionally omitted <==

==> picture [188 x 131] intentionally omitted <==

==> picture [155 x 141] intentionally omitted <==

==> picture [151 x 147] intentionally omitted <==

11 AGM Presentation July 2021

Dietary Supplements Developments & update

==> picture [225 x 34] intentionally omitted <==

==> picture [274 x 189] intentionally omitted <==

==> picture [478 x 58] intentionally omitted <==

----- Start of picture text -----

Sales increased by +9% in 1H 2021 v 1H 2020
----- End of picture text -----

==> picture [478 x 61] intentionally omitted <==

----- Start of picture text -----

Growth driven by rebound from COVID and launch of
two new supplements
----- End of picture text -----

==> picture [478 x 60] intentionally omitted <==

----- Start of picture text -----

“Cash Cow” business that contributed ~70% of 2020
Group revenue
----- End of picture text -----

==> picture [478 x 61] intentionally omitted <==

----- Start of picture text -----

Global Supplement market growing at 8.6% CAGR
from 2021-2028
----- End of picture text -----

• Source: https://www.grandviewresearch.com/industry-analysis/dietary-supplements-market

12 AGM Presentation July 2021

US Sales Rebounding Strongly iGalen restructure and relaunch

iGalen is Holista’s global distribution partner

US$

800,000 700,000 600,000 500,000 400,000 300,000 200,000 100,000 -

iGalen Month-on-Month Cumulative

Sales

==> picture [29 x 175] intentionally omitted <==

==> picture [28 x 157] intentionally omitted <==

==> picture [28 x 125] intentionally omitted <==

==> picture [29 x 79] intentionally omitted <==

==> picture [29 x 47] intentionally omitted <==

==> picture [28 x 31] intentionally omitted <==

==> picture [28 x 20] intentionally omitted <==

==> picture [28 x 11] intentionally omitted <==

==> picture [29 x 6] intentionally omitted <==

==> picture [342 x 35] intentionally omitted <==

• ✓ iGalen relaunched in August 2020

• ✓ Sales recovery with good margin driven by creative marketing and use of key influencers (e.g. former world boxing champions)

• ✓ Holista’s products appeared on popular Podcasts in the US including “Live with Les Brown”

• ✓ >US$750k (~A$1m) total revenue from iGalen alone in just nine months

• ✓ June sales of ~$200k will be recognised in 3Q 2021 due to change in payment gateway

13 AGM Presentation July 2021

Ovine Collagen Developments & update

==> picture [649 x 8] intentionally omitted <==

Guangzhou Sinbio Cosmetic Co Ltd trialling Holista’s patented collagen (via agreement with Mutiara Seribumi)

Sinbio to purchase 100% of Holista’s 48-tonne annual production capacity on successful trial (including regulatory approvals)

Sale price set at $75k/t (Holista can increase the price with 90-day notice)

Binding sales agreement to see Holista expand plant capacity to 576 tonnes over next four years

Secured $501,000 grant from WA Government to produce medical grade collagen

Holista to brand our collagen as Colligen™as “collagen made in Collie”

Guangzhou Sinbio is a Chinese state-owned enterprise that exclusively represents leading cosmetic brands like Ceeture, Estee Lauder and SK-II in China. It sells cosmetics via a network of 45,000 direct-owned stores.

==> picture [141 x 168] intentionally omitted <==

==> picture [74 x 74] intentionally omitted <==

==> picture [82 x 78] intentionally omitted <==

AGM Presentation July 2021

14

Board of Directors & Advisors Expertise to lead the group forward

==> picture [67 x 68] intentionally omitted <==

Daniel O’Connor Non-Exec Chairman

Over three decades commercialising intellectual property and has worked with R&D teams across Asia, North America, and Australia. He is the Consultant Principal of the on-line coaching and mentoring group Incubate IP and is a member of the UN Task Force on Innovation and Competitiveness.

==> picture [68 x 68] intentionally omitted <==

Rajen Manicka MD & CEO

Dr Manicka spent nine years working for Big Pharma including Roche and CIBA Pharmaceuticals in various capacities including product and marketing manager. He is a prominent figure in the Malaysian biotech industry and is a member of the Malaysian Ministry of Health Standing Committee for Traditional Medicine.

==> picture [75 x 76] intentionally omitted <==

Walter Joseph Non-Executive Director

Successful track record working in senior management and consulting positions over the past five decades at several leading organisations, including the National Australia Bank, WesfarmersBunnings, P&O Ports, Water Corporation of Western Australia (WA) and the WA Department of Commerce and Trade.

==> picture [67 x 68] intentionally omitted <==

Arthur Martin Advisor

Founder and President of GICC. Dr Martin invented Path-Away® and has conducted over 4,000 assessments for chem biological, bacterial and viral contamination. He pioneered the concept of “Prophylactic Air Management for Pathogen Control” and has an extensive list of publications and peer reviewed awards.

==> picture [67 x 67] intentionally omitted <==

Roscoe Moore Advisor

Dr Moore served as Assistant US Surgeon General, Rear Admiral of U.S. Public Health Service, Chief Epidemiologist with the Center for Device and Radiological Health at the U.S. FDA and Senior Epidemiologist within the National Institute for Occupational Safety and Health, Center for Disease Control (CDC).

Directors Chan Heng Fai and Blair Michelson retired from the board on 28 June 2021

15 AGM Presentation July 2021

Positive Outlook

Improved 2021 results expected

• ✓ Improving Outlook: YTD trading conditions show marked improvement over 2020

• ✓ Expanding Margins: Profit margins expected to improve on 2020 due to cost optimisation and organic growth

• ✓ Positive Tailwinds: Global trends supportive of further growth over medium- to longer-term for all divisions

• ✓ Sufficiently Resourced: funded to execute on current growth plans

Healthy Food

• Improved demand for GILite[TM] and 80Less[TM]

• Growing consumer focus on healthier foods to drive growth

• Early trials with other food manufacturers ongoing

Dietary Supplements

• 1H 2020 sales up 9% pcp

• New products contributing to growth

• Will remain significant cash generator for Holista

Infection Control

• Additional growth opportunities from new products (M3, Nasal Balm)

• Test kits business expanded to offer full range

Ovine Collagen

• Mutiara deal on track

• Major plant expansion if agreement becomes binding

• Capex fully funded from customer deposits, grants and internal resources

16 AGM Presentation July 2021

To join our mailing list please email: update@holistaco.com

Thank You

For further information, please contact: Corporate Matters: investor@holistaco.com General Enquiries: enquiries@holistaco.com Investor/Media Relations: Brendon Lau (m: 0409 341 613, e: brendon@vantagepointpartners.com.au)

==> picture [92 x 86] intentionally omitted <==

Disclaimer

This document has been prepared by Holista Colltech Limited and comprises written material/slides for a presentation concerning Holista Colltech Limited and its subsidiaries. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dispose of, or issue, or any solicitation of any offer to sell or otherwise dispose of, purchase, or subscribe for, any securities, nor does it constitute investment advice, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision.

Certain statements in this presentation are forward looking statements. You can identify these statements by the fact that they use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” and words of similar import. These forward looking statements speak only as at the date of this presentation. These statements are based on current expectations and beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such forward looking statements.

No representation, warranty or assurance (express or implied) is given or made by Holista Colltech Limited that the forward looking statements contained in this presentation are accurate, complete, reliable or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, Holista Colltech Limited and its respective officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss of damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom. Subject to any continuing obligation under applicable law or any relevant listing rules of the ASX, Holista Colltech Limited disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change of events, conditions, or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of Holista Colltech Limited since the date of this presentation.

==> picture [84 x 66] intentionally omitted <==

18 AGM Presentation July 2021